Diagnosis and Treatment of CD20 Negative B Cell Lymphomas

Authors

Tasleem Katchi, New York Medical College
Delong Liu, New York Medical CollegeFollow

Journal Title

Biomarker Research

First Page

5

Document Type

Article

Publication Date

2-1-2017

Department

Medicine

Abstract

CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.

Recommended Citation

Katchi, T., & Liu, D. (2017). Diagnosis and Treatment of CD20 Negative B Cell Lymphomas. Biomarker Research, 5, 5. https://doi.org/10.1186/s40364-017-0088-5

Publisher's Statement

Originally published in Biomarker Research 5:5. The original material can be found here.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.